PRINCETON, N.J., Feb. 22 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. , a leading provider of identity DNA testing services, today announced that Paul J. Kelly, M.D., chief executive officer of Orchid, is scheduled to present at the BIO CEO & Investor Conference in New York City on Wednesday, February 23, 2005 at 3:00 p.m. ET. Dr. Kelly will provide a brief corporate overview and discuss the company's recent progress.
A live and archived webcast of Dr. Kelly's presentation can be accessed via the Investor Relations section of Orchid's website at http://www.orchid.com/. The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the webcast at http://www.fulldisclosure.com/, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the webcast via Thomson's password-protected event management site, StreetEvents (http://www.streetevents.com/). The archived webcast will be available starting approximately one hour after the presentation and will be archived for 90 days.
About Orchid BioSciences
Orchid BioSciences is a leading provider of identity genetics services for the forensic and paternity DNA testing markets and for public health DNA testing for food safety. Orchid's strong market positions in these segments leverage the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the world-renowned Cellmark and GeneScreen brands that have been associated with exceptional quality, reliability, innovation and customer service for nearly two decades. More information on Orchid can be found at http://www.orchid.com/.
Orchid BioSciences, Inc.
CONTACT: Tracy J. Henrikson, Executive Director, CorporateCommunications of Orchid BioSciences, +1-609-750-2221